A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

BACKGROUND: Omarigliptin is a once-weekly (q.w.) oral DPP-4 inhibitor that is approved for the treatment of patients with type 2 diabetes mellitus (T2DM) in Japan. To support approval of omarigliptin in the United States, the clinical development program included a cardiovascular (CV) safety study....

Descripción completa

Detalles Bibliográficos
Autores principales: Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O’Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Lai, Eseng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594521/
https://www.ncbi.nlm.nih.gov/pubmed/28893244
http://dx.doi.org/10.1186/s12933-017-0593-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594521/
https://www.ncbi.nlm.nih.gov/pubmed/28893244
http://dx.doi.org/10.1186/s12933-017-0593-8

Ejemplares similares